Eledon Pharmaceuticals, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Vanguard Capital Management has reported a beneficial ownership of 5.05% in Eledon Pharmaceuticals Inc., holding 3,898,446 shares.
NASDAQ
BlackRock, Inc. has reported beneficial ownership of 5.8% of Eledon Pharmaceuticals, Inc.'s common stock as of March 31, 2026.
NASDAQ
The Vanguard Group has reported a 0% beneficial ownership in Eledon Pharmaceuticals Inc. following an internal realignment.
NASDAQ
SCHEDULE 13G/A: BlackRock Reduces Eledon Pharmaceuticals Stake Below 5%
BlackRock, Inc. has filed an amended Schedule 13G, disclosing its beneficial ownership in Eledon Pharmaceuticals, Inc. has fallen to 4.6% of common stock.
NASDAQ
Coastlands Capital and its affiliates, including Matthew D. Perry, have disclosed a significant passive stake in Eledon Pharmaceuticals, Inc., reaching up to 5.98% of common stock.
NASDAQ
The Vanguard Group has reported a 5.54% beneficial ownership stake in Eledon Pharmaceuticals Inc., holding over 3.3 million shares of common stock.
NASDAQ
SCHEDULE 13G: BlackRock Discloses 5.4% Stake in Eledon Pharmaceuticals
BlackRock, Inc. has reported a 5.4% beneficial ownership stake in Eledon Pharmaceuticals, Inc., holding over 3.25 million shares of common stock.
NASDAQ
Armistice Capital, LLC and Steven Boyd have reported a 4.99% beneficial ownership stake in Eledon Pharmaceuticals, Inc. as of December 31, 2024, through a Schedule 13G/A filing.
NASDAQ
Frazier Life Sciences and affiliated entities have filed an amended Schedule 13G/A, disclosing their updated passive beneficial ownership in Eledon Pharmaceuticals, Inc. as of December 31, 2024.